- Home
- XENE vs CORT Comparison
XENE vs CORT Comparison
Compare XENE & CORT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | XENE | CORT |
|---|---|---|
| Founded | 1996 | 1998 |
| Country | | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.2B | 3.7B |
| IPO Year | 2014 | 2001 |
Fundamental Metrics
Financial Performance| Metric | XENE | CORT |
|---|---|---|
| Price | $42.92 | $33.73 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 11 | 6 |
| Target Price | $54.09 | ★ $114.20 |
| AVG Volume (30 Days) | 747.0K | ★ 1.6M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 30.85 |
| EPS | N/A | ★ 0.62 |
| Revenue | $311,000.00 | ★ $675,040,000.00 |
| Revenue This Year | N/A | $23.03 |
| Revenue Next Year | N/A | $19.76 |
| P/E Ratio | ★ N/A | $64.49 |
| Revenue Growth | N/A | ★ 39.94 |
| 52 Week Low | $26.74 | $32.99 |
| 52 Week High | $46.60 | $117.33 |
Technical Indicators
Market Signals| Indicator | XENE | CORT |
|---|---|---|
| Relative Strength Index (RSI) | 56.04 | 30.84 |
| Support Level | $40.86 | $38.00 |
| Resistance Level | $43.67 | $40.51 |
| Average True Range (ATR) | 1.56 | 2.61 |
| MACD | 0.16 | 0.46 |
| Stochastic Oscillator | 80.56 | 37.79 |
Price Performance
Historical ComparisonAbout XENE Xenon Pharmaceuticals Inc.
Xenon Pharmaceuticals Inc is a neuroscience-focused biopharmaceutical company committed to improving the lives of people living with neurological and psychiatric disorders. It is advancing a novel product pipeline to address areas of high unmet medical need, including epilepsy and depression. The product candidates of the group include XEN1101, NBI-921352, and XEN496 for Epilepsy and Nav1.7 oral inhibitors for Pain.
About CORT Corcept Therapeutics Incorporated
Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic and neuropsychiatric disorders by modulating the effect of the hormone cortisol. The company's compounds are being evaluated in clinical trials as potential treatments for a variety of serious disorders - hypercortisolism, advanced ovarian cancer, prostate cancer, ALS, and MASH.